UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 7, 2008

QUESTCOR PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

California (State or Other Jurisdiction of Incorporation)		001-14758 (Commission File Number)		33-0476164 (I.R.S. Employer Identification No.)

3260 Whipple Road Union City, California (Address of Principal Executive Offices)		94587 (Zip Code)

Registrant’s telephone number, including area code: (510) 400-0700

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Determination of 2008 Base Salaries
On January 7, 2008, the Board, based on the recommendation of Questcor Pharmaceuticals, Inc.’s (the “Company”) Compensation Committee, approved the 2008 annual base salaries for the Company’s executive officers.

The table below sets forth the 2008 annual base salary levels for the following executive officers:

Name		Title		2008 Salary
Don M. Bailey		President and Chief Executive Officer		$	525,000
Stephen L. Cartt		Executive Vice President, Commercial Development		$	350,000
Steven Halladay, Ph.D.		Senior Vice President, Clinical and Regulatory Affairs		$	295,000
David J. Medeiros		Senior Vice President, Pharmaceutical Operations		$	325,000
George M. Stuart		Senior Vice President, Finance and Chief Financial Officer		$	260,000

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.